Julia Wattacheril, MD
Transplant Hepatology · New York, NYNPI 1811180359
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,018 of the $36,912 with a category attached, or 73.2%. 7 manufacturers reported payments, led by GSK at 38.3% of the total. Reporting peaked in 2019 at $15,050 and has fallen 76.5% since, to $3,538 in 2025.
Across 22 payments — averaging $1677.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$14K
- AstraZeneca$13K
- Astrazeneca UK Limited$9K
- Janssen Research & Development, LLC$324
- AbbVie$41
- Pentax Of America, Inc.$23
- plus $22 from 1 others
Across 79 payments — averaging $4257.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$161K
- Janssen Research & Development, LLC$94K
- Intercept Pharma Europe Ltd.$54K
- Regeneron$27K
What the payments were for
- Consulting fees$27,01873%
- Travel & lodging$9,44626%
- Food & beverage$4491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $14,124 |
| AstraZeneca | 4 | $13,197 |
| Astrazeneca UK Limited | 8 | $9,182 |
| Janssen Research & Development, LLC | 1 | $324 |
| AbbVie | 1 | $41 |
| Pentax Of America, Inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
How this compares
$36,912 in reported general payments places this provider in the 85th percentile of 36 transplant hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant hepatology in New York
- Nikolaos PyrsopoulosNew York$251K
- James ParkNew York$81K
- Amon AsgharpourNew York$58K
- Giuseppe CullaroNew York$50K
- Gene ImNew York$15K
- Elizabeth VernaNew York$11K
- Rajani SharmaNew York$11K
- Annmarie LiapakisNew York$10K
- Alyson FoxNew York$10K
- Linda LawNew York$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.